期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

2型糖尿病治疗的新药——维格列汀 被引量：1

原文传递
导出
摘要 2型糖尿病以胰岛素抵抗为特征，表现为胰岛13细胞进行性衰竭，从而导致糖负荷后胰岛素分泌不足，以及损伤肠促胰岛素对糖的反应。长期的高血糖将导致严重的微血管和大血管并发症。
作者 徐焱成 邹润梅
机构地区 武汉大学中南医院内分泌科
出处 《医学新知》 CAS 2011年第2期87-89,共3页 New Medicine
关键词 2型糖尿病 治疗 维格列汀
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献29

  • 1Holman R R,Paul S K, bethel M A,et al. 10 -year follow -up of intensive glucose control in type 2 diabetes[ J]. N Engl J Med ,2008, 359 : 1577-1589.
  • 2McKennon S A, Campbell R K. the physiology of incretin hormones and the basis for DPP - 4 inhibitors [ J ]. Diabetes Educ, 2007,33 : 55 -66.
  • 3Nauek M A, baller b, Meier J J. Gastric inhibitory polypeptide and glucagon - like peptide - I in the pathogenesis of type 2 diabetes [ J ]. Diabetes,2004, (53 suppl 3 ) : S190-196.
  • 4Perfetti R, Merkel P. Glueagon - like peptide - 1 :a major regulator of pancreatic beta - cell function [ J ]. Eur J Endocrinol, 2000,143:717 - 725.
  • 5Ahren b, Iandin -Olsson M,Jansson P A, et al. Inhibition of di - peptidyl peptidase - 4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes [ J ]..J Clin Endocri - nol Metab ,2004,89:2078-2084.
  • 6Aschner P, Kipnes M S, luneeford J K, et al. Effect of the dipep - tidyl peptidase -4 inhibitor sitagliptin as monotherapy on gly - cemic control in patients with type 2 diabetes[ J ]. Diabetes Care,2006,29 : 2632-2637.
  • 7Brandt I, Joossens J, Chen X,et al. Inhibition of dipeptidyl - pepti - dase IV catalyzed peptide truncation by Vildagliptin ((2S) - { [ (3 - hy - droxyadamantan - 1 - yl) amino ] acetyl } - pyrrolidine - 2 - carbonitrile) [ J ]. biochem Pharmacol. , 2005,70 : 134 -143.
  • 8Bergman A. , Ebel D, Liu F , et al. Absolute bioavailability of sitagliptin,an oral dipeptidyl peptidase -4 inhibitor, in healthy volunteers [ J ].Biopharmaeeutics and Drug Disposition, 2007,28 : 315- 322.
  • 9Pi - Sunyer F X, Schweizer A, Mills D,et al. Efficacy and toler - ability of vildagliptin monotherapy in drug - naive patients with type 2 diabetes[ J]. Diabetes Res Clin Pract,2007,76 : 132-138.
  • 10Bergman A J,Coyte J, Yi B. Effect of renal insufficiency on the pharmacokinetics of MK - 0431 (sitagliptin) , a selective dipeptidyl - peptidase - IV ( DPP - IV ) inhibitor (Abstract) [ J ]. ClinPharmacol Therapeut ,2006,38: P11-46.

同被引文献16

  • 1贾伟平.肠促胰素类药物治疗2型糖尿病的评价及展望[J].中华糖尿病杂志,2010,2(6). 被引量：4
  • 2夏玲红.治疗糖尿病的新药西他列汀[J].中国新药杂志,2007,16(12):979-981. 被引量：28
  • 3Holman P R, Paul S K, bethel M A, et al. 10 -year-follow -up of in- tensive glucose control in type 2 diabetes. N Engl J Med, 2008,359: 1577.
  • 4Pi - Sunyer F, SchweizerA , Mills D, et al. Efficacy and tolerability of vildagliptin mono therapy in drug - naivepatients with type 2 diabetes. Diabetes Research and Clinical Practice ,2007,76 (1) :132.
  • 5Azumak, Mancion J. Measurements of islet function and glucose metab- olism with the DPP -4 inhibitor vildagliptin in patients with type 2 dia- betes. J Clin Endocrinol Metab, 2008,93:459.
  • 6Ahrenb, Landin, Jansson P A, et al. Inhibition of dipeptidyl peptidase -4 reduces glycemia, sustains insulin levels, and reduces glu- cagon levels in type 2 diabetes. J Clin Endocrinol Metab,2004,89:2078.
  • 7Bergman A, Ebcld, LiuF, et al. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase - 4 inhibitor in healthy volunteers. Biophar- maceutics and Drug Disposition ,2007,28:315.
  • 8Pratleyre, Salsalia, Matfin G. Inhibition of dipeptidyl peptidase - 4 with vildagliptin : a potential new treatment for type 2 diabetes. Br J Diabetes Vasc Dis ,2006,6(4) :150.
  • 9Mckennon S A, Campbell R K. the physiology of incretin hormones and the basis for DPP- 4 inhibitors. Diabetes Educ ,2007,33:55.
  • 10BOSIE,CAMISASCAPP,COLLOBERC, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes ina- clequately controlled with mefformin. Diabetes Care,2007,30(4) : 890.

引证文献1

二级引证文献6

医学新知
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部